United Nations: America’s top infectious disease expert Dr Anthony Fauci has said that he is cautiously optimistic over the results from the current clinical trials and the possibility of developing a vaccine for COVID-19 by the end of this year or early next year.
Fauci, the National Institute of Allergy and Infectious Diseases Director, said that the coronavirus will likely to continue to emerge, and global collaboration and transparency are critical to deal with the future pandemics.
“The lessons we’ve learned from the coronavirus is they have pandemic potential, they’re likely to continue to emerge. Good public health measures are critical to controlling them.
Global collaboration and transparency are critical if we are to get a containment of this extraordinary assault on the human population, a viral disease that spreads rapidly and as a high degree of morbidity and mortality, he said in his recorded remarks during an online session on Confronting COVID-19 Through Innovation and Research: Lessons Learned from the Pandemic’. The event is part of a series of online dialogue by the United Nations Academic Impact (UNAI) dubbed ’75 for UN75: 75 Minutes of Conversation’ that brings together academics, researchers and students from around the world.
Giving an overview of the pandemic and efforts to develop a vaccine, Fauci said: we’ve adapted a strategic approach to get multiple candidates and there are more than one candidate vaccine to be conducted in trials in a harmonised way so that we use standard endpoints, standard and single data and safety monitoring board as well as identical immunological parameters that are measured, so that you could bridge one study to another.
There are a number of vaccine candidates already in clinical trial and a few out of those candidates have completed phase 1/2 status, he said, adding that there are trials that will be going into phase three sometime at the end of July and then others will follow in the months of August, September and October.
Fauci said hopefully we’ll be able to get some information, such as with this particular one representative vaccine that we started here in January. Phase one looks good, very promising data on the induction of neutralising antibody and will go into trial at the end of July. (PTI)